Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients

Xu‐Chao Zhang(Guangdong Academy of Medical Sciences), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Enrique Zudaire(Centro de Investigación del Cáncer), Zayed Albertyn(Craft Technologies (United States)), Suso Platero(Janssen (United States)), Matthew V. Lorenzi(Johnson & Johnson (United States)), Jingyu Zhang, Qun Wang(Sun Yat-sen University), Jun Wang(Peking University), Bo Wang(Institute of Molecular and Cell Biology), Lin Xu(Guangdong Pharmaceutical University), Ying Cheng, Jennifer Yang(Women's and Children's Hospital), Yue Fan(Shanghai Jiao Tong University), Guoguang Shao(Jilin University), Xiaotao Qu(The Affiliated Yongchuan Hospital of Chongqing Medical University), Christopher Moy(GlaxoSmithKline (United States)), Xiayu Huang, Yang Qiu(Beijing Proteome Research Center)
Nature Communications
April 16, 2019
10.1038/s41467-019-09762-1
Cited by 231

Related Papers

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k